An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients ≥ 65 Years With Acute Myeloid Leukemia

Trial Profile

An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients ≥ 65 Years With Acute Myeloid Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Volasertib (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Dec 2016 Status changed from active, no longer recruiting to discontinued.
    • 28 Oct 2016 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
    • 28 Oct 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top